These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 9818761)

  • 1. In-vitro activities of cefepime and other beta-lactam antibiotics against clinical isolates from a Colombian teaching hospital.
    Mattar S; Sánchez L; Pérez D; Arango A; Parodi R; Muelle C
    J Antimicrob Chemother; 1998 Oct; 42(4):550-2. PubMed ID: 9818761
    [No Abstract]   [Full Text] [Related]  

  • 2. Activity of cefepime against nosocomial blood culture isolates.
    Qadri SM; Cunha BA; Ueno Y; Abumustafa F; Imambaccus H; Tullo DD; Domenico P
    J Antimicrob Chemother; 1995 Sep; 36(3):531-6. PubMed ID: 8830018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro activity of cefepime and other antimicrobials: survey of European isolates.
    Thornsberry C; Brown SD; Yee YC; Bouchillon SK; Marler JK; Rich T
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():31-53. PubMed ID: 8150766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fourth-generation cephalosporins: in vitro activity against nosocomial gram-negative bacilli compared with beta-lactam antibiotics and ciprofloxacin.
    Tumah H
    Chemotherapy; 2005 May; 51(2-3):80-5. PubMed ID: 15870501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HR 810 and BMY-28142, two new cephalosporins with broad-spectrum activity: an in-vitro comparison with other beta-lactam antibiotics.
    Clarke AM; Zemcov SJ; Wright JM
    J Antimicrob Chemother; 1985 Mar; 15(3):305-10. PubMed ID: 3838981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activities of six extended spectrum beta-lactam antibiotics against clinically significant gram-negative bacteria.
    Van haute I; Verschraegen G
    Diagn Microbiol Infect Dis; 1998 Jul; 31(3):485-7. PubMed ID: 9635242
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative study on resistant pattern of clinical isolates against levofloxacin and cefepime.
    Nasiri MI; Naqvi SB; Zaidi AA; Saeed R; Raza G
    Pak J Pharm Sci; 2013 Mar; 26(2):415-9. PubMed ID: 23455216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The comparative activity of cefepime and other current antibiotics against microorganisms isolated from patients in pediatric intensive therapy units].
    Kurchavov VA; Beloborodova NV; Biriukov AV; Vostrikova TIu; Rogatina EL; Krutskikh EN
    Antibiot Khimioter; 1999; 44(11):23-30. PubMed ID: 10629738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro activity of cefpirome (HR-810), WIN-49375, BMY-28142 and other antibiotics against nosocomially important isolates from cancer patients.
    Rolston KV; Alvarez ME; Hsu KC; Bodey GP
    J Antimicrob Chemother; 1986 Apr; 17(4):453-7. PubMed ID: 3458694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The results of a multicenter study of the comparative activity of cefepime and other antibiotics against the causative agents of severe hospital infections (the Micromax program)].
    Sidorenko SV; Strachunskiĭ LS; Akhmedova LI; Beloborodov VB; Bogomolova NS; Bol'shakov LV; Dekhnich AV; Karabak VI; Malikov VE; Pavlova MV; Polikarpova SV; Rudnov VA; Iakovlev VP
    Antibiot Khimioter; 1999; 44(11):7-16. PubMed ID: 10629736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of cefepime and cefpirome compared to other third-generation cephem antibiotics against gram-negative nosocomial pathogens.
    Tumah HN
    Pharmazie; 2004 Nov; 59(11):854-8. PubMed ID: 15587586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Multicenter evaluation of the antimicrobial activity in vitro for six broad-spectrum beta-lactams in China using the E-test method].
    Xu Y; Chen M; Zhang S
    Zhonghua Yi Xue Za Zhi; 2000 May; 80(5):362-5. PubMed ID: 11798789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparative in vitro activity of cefepime and other antibiotics against clinical strains of gram-negative bacteria].
    Beloborodova NV; Vostrikova TIu; Mel'ko AI
    Antibiot Khimioter; 2003; 48(7):12-5. PubMed ID: 14628572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [In vitro study of antibacterial activity of cefepime (Axepim) against gram negative bacteria: comparison with cephalosporins and other beta-lactams].
    Vachée A; Devalckenaere A; Husson MO; Izard D
    Pathol Biol (Paris); 1996 Feb; 44(2):132-7. PubMed ID: 8761598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of the in-vitro activity of cefepime and other antimicrobial agents against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
    Yee YC; Thornsberry C; Brown SD; Bouchillon SK; Marler JK; Rich T
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():13-9. PubMed ID: 8150756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility of Klebsiella spp. to cefpirome and cefepime.
    Tuchiluş C; Poiată A; Iancu LS; Bădicuţ I; Ambăruş A; Buiuc D
    Rev Med Chir Soc Med Nat Iasi; 2006; 110(2):465-7. PubMed ID: 17802963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of sensitivity of different organisms to cefepime and tazobactum (megapime XP) in comparison to cefepime and ceftazidime.
    Pal RB; Pal P; Venkatesh V; Kulkarni KP
    J Indian Med Assoc; 2008 Sep; 106(9):605-6, 611. PubMed ID: 19552092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro selection of beta-lactam resistance by exposure to second, third, and fourth generation cephalosporins.
    Murray PR
    Chemioterapia; 1985 Feb; 4(1):78-82. PubMed ID: 3872726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.
    Sader HS; Rhomberg PR; Flamm RK; Jones RN; Castanheira M
    J Antimicrob Chemother; 2017 Jun; 72(6):1696-1703. PubMed ID: 28333332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.